UP!

GHL $14.99

GHL target price
14.99
0
0
Greenhill
Type
Public company
Traded as NYSE: GHL
S&P 600 Component
Industry Investment Banking
Founded 1996; 21 years ago (1996)
Headquarters 300 Park Avenue (Manhattan)
New York City, United States
Key people

Robert F. Greenhill (Chairman and Founder)

Scott L. Bok (CEO)
Products Investment Banking
Revenue Increase $336 million (2016)
Net income
Increase $61 million (2016)
Website www.greenhill.com

Robert F. Greenhill (Chairman and Founder)

Greenhill is an independent, New York based investment bank founded in 1996 by Robert F. Greenhill. It is widely considered to be one of the most elite and prestigious firms on Wall Street, with a formidable M&A practice.

The firm provides advice on mergers, acquisitions, restructurings, financings, and capital raisings to leading corporations, partnerships, institutions and governments across a number of industries. Recent clients include Actavis, Alcoa, Energy Future Holdings, Fluor Corporation, Gannett, GlaxoSmithKline, London Stock Exchange Group, Safeway, Tesco, Teva, and the US Department of Treasury.

Greenhill was established in New York City in 1996 by Robert F. Greenhill, the former President of Morgan Stanley and former Chairman and Chief Executive Officer of Smith Barney. He founded the first M&A group on Wall Street while at Morgan Stanley and became an early pioneer of the industry.

Greenhill has been featured in many prominent assignments since its founding including the $100 billion acquisition of ABN AMRO in 2007, the United States Department of Treasury's divestiture of its $51 billion stake in AIG in 2012, and the $17 billion merger between Northwest Airlines and Delta Air Lines in 2008. The firm was also involved as an adviser to a highly influential group of former Morgan Stanley partners in their successful and controversial bid to have former Morgan Stanley CEO Philip J. Purcell step down in 2005.

Like a number of other independent investment banks, Greenhill has grown by recruiting a significant number of Managing Directors from major investment banks (as well as senior professionals from other institutions). The firm has also expanded globally, opening further offices in North America, Europe, Australasia, Asia and South America.

In May 2004, the firm completed an initial public offering of common stock onto the New York Stock Exchange.

In October 2013, the firm announced that it had opened an office in São Paulo in conjunction with hiring Daniel Wainstein, the former head of Goldman Sachs' Brazilian investment banking business.

In 2014, Greenhill advised on the $25 billion acquisition of Forest Laboratories by Actavis and the $10 billion merger between Safeway and Albertsons. Both transactions were among the ten largest of the year globally.

In January 2015, Greenhill agreed to purchase Cogent Partners, a leading investment bank focused on secondary market advisory for private equity investments.

In July 2015, Greenhill advised Teva Pharmaceuticals on the $40.5 billion acquisition of Allergan plc’s Generics business in one of the largest transactions globally in 2015.

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q3 2022 2022-11-01 Future report Set alerts
Q2 2022 2022-08-02 -1.03 -1.03
Q1 2022 2022-04-27 -0.66 -0.66
Q4 2021 2022-02-02 1.21 1.21
Q3 2021 2021-11-03 0.85 0.85
Q2 2021 2021-08-03 -0.45 -0.45
Q1 2021 2021-04-29 0.09 0.09
Q4 2020 2021-02-04 2.71 2.71
Q3 2020 2020-11-02 -0.49 -0.49
Q2 2020 2020-07-23 -0.79 -0.79

Ratings

2016-06-29 Reiterated Rating Credit Suisse Hold $13.00
2016-06-29 Reiterated Rating Credit Suisse Group AG Hold $13.00
2016-04-08 Lower Price Target Credit Suisse Neutral $24.00 to $18.00
2016-04-06 Downgrade Goldman Sachs Buy to Neutral $33.00 to $25.00
2016-04-06 Downgrade Goldman Sachs Group Inc. Buy to Neutral $33.00 to $25.00
2016-03-15 Lower Price Target Nomura $29.00 to $28.00
2016-03-15 Lower Price Target Nomura Holdings Inc. $29.00 to $28.00
2016-01-29 Upgrade Rafferty Capital Markets Hold to Buy $27.00 to $34.00
2016-01-11 Boost Price Target Nomura Neutral $26.00 to $28.00
2015-12-21 Initiated Coverage Buckingham Research Neutral $32.00
2015-10-23 Lower Price Target Susquehanna $39.00 to $33.00
2015-10-23 Lower Price Target Nomura Neutral $30.00 to $26.00
2015-10-23 Lower Price Target Keefe, Bruyette & Woods $35.00 to $32.00
2015-10-23 Lower Price Target Credit Suisse Neutral $31.00
2015-10-12 Lower Price Target Susquehanna Positive $46.00 to $39.00
2015-10-07 Lower Price Target Keefe, Bruyette & Woods Market Perform $45.00 to $35.00
2015-10-06 Lower Price Target Nomura Neutral $41.00 to $30.00
2015-09-08 Upgrade Credit Suisse Underperform to Neutral $36.50 to $34.00
2015-07-07 Boost Price Target Nomura $41.00 to $42.00
2015-06-25 Upgrade Goldman Sachs Sell to Buy $41.00 to $48.00
2015-04-13 Boost Price Target Susquehanna Positive $46.00 to $48.00
2015-02-18 Set Price Target Credit Suisse Sell $34.00 to $36.50
2015-02-17 Upgrade Susquehanna Neutral to Positive
2015-02-02 Downgrade Credit Suisse Neutral to Underperform $45.00 to $34.00
2015-01-29 Lower Price Target Keefe, Bruyette & Woods Market Perform $50.00 to $42.00
2015-01-29 Lower Price Target Nomura Neutral $44.00 to $38.00
2015-01-29 Lower Price Target MKM Partners Neutral $47.00 to $40.00
2015-01-13 Downgrade Goldman Sachs Neutral to Sell $41.00 to $37.00
2014-12-12 Lower Price Target Keefe, Bruyette & Woods Market Perform $54.00 to $50.00
2014-12-11 Initiated Coverage MKM Partners Hold
2014-07-29 Lower Price Target Susquehanna $43.00 to $40.00
2014-07-29 Lower Price Target Nomura Neutral $49.00 to $45.00
2014-07-29 Boost Price Target Credit Suisse Neutral $46.00 to $47.00
2014-07-07 Reiterated Rating Susquehanna Neutral $46.00 to $43.00
2014-06-25 Upgrade Sandler O'Neill Hold to Buy
2014-05-12 Boost Price Target Goldman Sachs $46.00 to $48.00
2014-05-05 Upgrade Rafferty Capital Markets Hold to Buy
2014-04-16 Upgrade Nomura Reduce to Neutral $49.00
2014-03-12 Initiated Coverage Sidoti Neutral
2014-01-09 Initiated Coverage Nomura Reduce $52.00
2013-12-10 Initiated Coverage Credit Suisse Neutral
2013-10-08 Lower Price Target Sandler O'Neill Hold $50.00 to $48.00
2013-09-17 Boost Price Target Susquehanna Neutral $43.00 to $46.00
2012-10-09 Initiated UBS Neutral $52
2011-10-07 Upgrade Ticonderoga Neutral to Buy $37
2011-07-20 Upgrade Ticonderoga Sell to Neutral $44
2011-02-18 Downgrade Ticonderoga Neutral to Sell $60
2010-09-13 Downgrade Ticonderoga Buy to Neutral
2010-03-17 Upgrade Keefe Bruyette Mkt Perform to Outperform
2010-03-01 Upgrade JMP Securities Mkt Perform to Mkt Outperform
2009-09-30 Downgrade Pali Research Buy to Neutral
2009-07-10 Initiated William Blair Outperform
2009-04-15 Initiated Pali Research Buy
2009-04-14 Initiated JMP Securities Mkt Perform
2008-12-30 Downgrade Keefe Bruyette Outperform to Mkt Perform
2008-09-12 Upgrade Wachovia Mkt Perform to Outperform
2008-06-06 Downgrade Wachovia Outperform to Mkt Perform
2016-06-29 Reiterated Rating Credit Suisse Hold $13.00
2016-06-29 Reiterated Rating Credit Suisse Group AG Hold $13.00
2016-04-08 Lower Price Target Credit Suisse Neutral $24.00 to $18.00
2016-04-06 Downgrade Goldman Sachs Buy to Neutral $33.00 to $25.00
2016-04-06 Downgrade Goldman Sachs Group Inc. Buy to Neutral $33.00 to $25.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
Pacific Coast Energy Co LP 13.66%  (3866497) GHL / ROYT /
Greenhill Capital Partners II L P 13.66%  (3866497) GHL / ROYT /
GREENHILL & CO INC Director by Deputization 6.40%  (1813387) GHL / IRDM /
BOK SCOTT L Chief Executive Officer 2.74%  (776436) GHL /
GREENHILL ROBERT F Chairman 2.05%  (579710) GHL /
RODRIGUEZ HAROLD J JR Chief Operating Officer 0.20%  (56922) GHL /
GOLDSTONE STEVEN F 0.12%  (34002) CAG / CHEF / GHL /
Wyles David President 0.10%  (29242) GHL /
Costantino Kevin M President 0.08%  (24046) GHL /
KEY STEPHEN L 0.07%  (21153) GHL /
ROBARDS KAREN P 0.05%  (14435) ATRC / GHL /
DANFORTH JOHN C 0.04%  (10485) CERN / GHL /
LIU JOHN D 0.03%  (8691) GHL / WHR /
BLAKELY ROBERT T 0.03%  (8261) ALLY / GHL / NRP / WLK /
Grubb Christopher Thomas Chief Financial Officer 0.02%  (5416) GHL /
Solotar Gavin Dean General Counsel 0.02%  (5333) GHL /
Moran Patricia Chief Legal Officer 0.01%  (3765) GHL /